𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy

✍ Scribed by Keiran S.M. Smalley; Meenhard Herlyn


Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
144 KB
Volume
124
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

There is growing evidence to suggest that not all cancer cells have similar levels of malignant potential and that tumor progression may be driven by specialized sub‐sets of “tumor initiating” cells. It is likely that as tumor initiating cells have lower proliferation rates and enhanced survival mechanisms they may also drive drug resistance. Melanoma is known to be an exceptionally therapy resistant tumor, with no treatment yet identified to alter the natural progression of the disseminated disease. In the current review, we discuss evidence for the existence of melanoma initiating cells and described possible therapeutic strategies to eradicate this population via the targeting of specific cell‐surface markers or through the disruption of the interaction of the melanoma initiating cells with their local microenvironment. It is hoped that the targeting of melanoma initiating cells may be one approach to overcome the incredible therapy resistance of this tumor. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


STAT3 is essential for the maintenance o
✍ Claire Villalva; Severine Martin-Lannerée; Ulrich Cortes; Fatima Dkhissi; Michel 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 762 KB

## Abstract Glioblastoma (GBM), the highest‐grade form of gliomas, is the most frequent and the most aggressive. Recently, a subpopulation of cells with stem cells characteristics, commonly named “tumor‐initiating stem cells” (TISCs) or “cancer stem cells” (CSCs) were identified in GBM. These cells